Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons.
about
Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknownHSV-2: in pursuit of a vaccineSeroepidemiology of Herpes Simplex virus type 1 and 2 in Western and Southern Switzerland in adults aged 25-74 in 1992-93: a population-based studyThe estimated economic burden of genital herpes in the United States. An analysis using two costing approachesPrevention of genital herpes in a guinea pig model using a glycoprotein D-specific single chain antibody as a microbicideThe molecular basis of herpes simplex virus latencyMathematical Modeling Predicts that Increased HSV-2 Shedding in HIV-1 Infected Persons Is Due to Poor Immunologic Control in Ganglia and Genital MucosaThree-Dimensional Rotating Wall Vessel-Derived Cell Culture Models for Studying Virus-Host InteractionsThe scarlet HHerpes simplex virus-2 transmission probability estimates based on quantity of viral sheddingOral shedding of herpes simplex virus type 2.Virologic and immunologic evidence of multifocal genital herpes simplex virus 2 infection.Asymptomatic human CD4+ cytotoxic T-cell epitopes identified from herpes simplex virus glycoprotein BCD4 T-cell responses to herpes simplex virus type 2 major capsid protein VP5: comparison with responses to tegument and envelope glycoproteins.Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa.Cytomegalovirus: pathogen, paradigm, and puzzleImpact of HIV infection and Kaposi sarcoma on human herpesvirus-8 mucosal replication and dissemination in Uganda.Clinical reactivations of herpes simplex virus type 2 infection and human immunodeficiency virus disease progression markers.New concepts in understanding genital herpes.Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs.Overlapping reactivations of herpes simplex virus type 2 in the genital and perianal mucosa.Herpes simplex virus (HSV)-specific T cells activated in the absence of IFN-gamma express alternative effector functions but are not protective against genital HSV-2 infection.Frequent release of low amounts of herpes simplex virus from neurons: results of a mathematical model.Diagnosis of genital herpes simplex virus infection in the clinical laboratoryAsymptomatic HLA-A*02:01-restricted epitopes from herpes simplex virus glycoprotein B preferentially recall polyfunctional CD8+ T cells from seropositive asymptomatic individuals and protect HLA transgenic mice against ocular herpes.Herpes simplex virus type 2 seropositivity and relationship status among U.S. adults age 20 to 49: a population-based analysis.Recent advances: Sexually transmitted infections.Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2.Prevalence and risk factors associated with herpes simplex virus-2 infection in a contemporary cohort of HIV-infected persons in the United StatesPublic TCR use by herpes simplex virus-2-specific human CD8 CTLs.Recurrent vaginal shedding of herpes simplex type 2 virus in the mouse and effects of antiviral therapy.APOE genotype is associated with oral herpetic lesions but not genital or oral herpes simplex virus shedding.Six-year study of the incidence of herpes in genital and nongenital cultures in a central Kentucky medical center patient populationNovel approach for specific detection of herpes simplex virus type 1 and 2 antibodies and immunoglobulin G and M antibodies.Expression of cutaneous lymphocyte-associated antigen and E-selectin ligand by circulating human memory CD4+ T lymphocytes specific for herpes simplex virus type 2.Homing in on the cellular immune response to HSV-2 in humans.Seroprevalence and risk factors of herpes simplex virus type-2 infection among pregnant women in Northeast India.The cotton rat provides a novel model to study genital herpes infection and to evaluate preventive strategies.Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: a phase II, randomized, double-blind, placebo-controlled studyMucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes
P2860
Q21296712-83ED12A8-91C7-4830-A382-C7635C718D2FQ22306291-C03DE24E-1A8B-433B-B1FD-8739643376EDQ24791873-56FF026A-6C9A-4CCB-9C34-9D98362298E3Q24801371-1E375DE7-D41B-475D-AE98-9987A51AC5CAQ24803342-4B49CB74-1DBB-40DA-A7C3-D9A731EC3ADAQ27001272-B3296FD1-C147-4252-8C49-16316788723FQ27347896-CA67AF6C-3492-4692-A69A-AF1963516269Q28072615-A024BD94-3CA5-42A5-B3C7-BA187712BB9AQ28114465-6AC65E13-5AF8-466D-8A46-573DE52CE7E4Q28236882-C2E7D66A-0F65-496E-AA09-AD43BFB45676Q30478605-DD9BBCAE-380E-43DD-BF76-CA82B7CE57CAQ30576590-5C502B7F-D740-4E42-A63B-7194163574C3Q30847945-2D20272D-30D2-43F5-88E9-1B6962F4C4DCQ30957753-EAADE246-3419-445F-92A0-B35EC166465FQ33336603-CE02E2EC-E055-492B-8B05-8650FCF950A5Q33351523-5C15BC16-2EDB-410F-B2A1-9A089FAC101DQ33401242-FD023866-5356-4B14-98DA-962A2DB5924BQ33550768-C636CE13-9342-438D-8EBC-C1EA166480B5Q33582145-478AA61D-8F19-4BBA-BFAC-37B734E32C40Q33595097-6C67C62F-2E30-4ED1-A9BA-5F25537DF14DQ33611115-032F3A06-3F41-4848-B254-68025BD69AB7Q33625030-2AC7D61A-9D4B-4353-A365-A6F39066ABBEQ33638754-DCF2F889-8C49-47B7-AB15-5F5E86C1F9CAQ33655295-E47862F8-44C9-41E4-AAD8-49DB2ED5A83CQ33755236-C4C6CEC1-C4B9-46E5-9D98-240AADE49052Q33777593-6A21335E-0549-4CAA-AC12-98BFA23BB775Q33805422-0519912D-677F-47E8-9C64-F4141C85D602Q33810615-64A3D1C3-0732-40F6-8920-409568DC0755Q33813876-F05BA195-3C9C-49BF-B541-E7589D93CFECQ33824488-F2687513-81AD-47A7-BA01-AD8FE5F37922Q33885018-7BD96ECA-5962-49D8-8A58-E2C8450AA055Q33895582-C1E66859-47E9-4FF0-A6A6-37AC7EDA736DQ33973461-3522DCBF-4492-4E84-A7EA-AF72AB9EAE61Q33998722-4828BE31-AF43-42CD-AA66-DC3F583F7ED8Q34081662-8DC9E256-1095-4FF1-86DF-33D090012F31Q34081670-2D99BACA-FED0-4E18-B3CF-861B00F413D3Q34082025-4B982496-0770-4836-9B8A-C630B669C23CQ34142834-4DD8023B-C186-4552-A1F8-EA8729E12C87Q34144914-DC628DAF-0C13-4188-944E-B647D67E0515Q34279175-DE1FD047-CE0A-414E-B53E-E809D91D8C7C
P2860
Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Reactivation of genital herpes ...... ptomatic seropositive persons.
@en
Reactivation of genital herpes ...... ptomatic seropositive persons.
@nl
type
label
Reactivation of genital herpes ...... ptomatic seropositive persons.
@en
Reactivation of genital herpes ...... ptomatic seropositive persons.
@nl
prefLabel
Reactivation of genital herpes ...... ptomatic seropositive persons.
@en
Reactivation of genital herpes ...... ptomatic seropositive persons.
@nl
P2093
P1476
Reactivation of genital herpes ...... ptomatic seropositive persons.
@en
P2093
Krieger JN
Ryncarz AJ
P304
P356
10.1056/NEJM200003233421203
P407
P50
P577
2000-03-01T00:00:00Z